

Siyuan Zheng

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2889143/publications.pdf>

Version: 2024-02-01

45
papers

14,704
citations

257101

24
h-index

264894

42
g-index

51
all docs

51
docs citations

51
times ranked

22724
citing authors

#	ARTICLE	IF	CITATIONS
1	The Somatic Genomic Landscape of Glioblastoma. <i>Cell</i> , 2013, 155, 462-477.	13.5	3,979
2	Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. <i>New England Journal of Medicine</i> , 2015, 372, 2481-2498.	13.9	2,582
3	Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. <i>Cell</i> , 2017, 169, 1327-1341.e23.	13.5	1,794
4	Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. <i>Cell</i> , 2016, 164, 550-563.	13.5	1,695
5	Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. <i>Cancer Cell</i> , 2017, 32, 42-56.e6.	7.7	1,282
6	Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. <i>Cancer Cell</i> , 2016, 29, 723-736.	7.7	482
7	Systematic analysis of telomere length and somatic alterations in 31 cancer types. <i>Nature Genetics</i> , 2017, 49, 349-357.	9.4	476
8	Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. <i>Cell Reports</i> , 2017, 18, 2780-2794.	2.9	416
9	Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution. <i>Genome Research</i> , 2015, 25, 316-327.	2.4	343
10	Discordant inheritance of chromosomal and extrachromosomal DNA elements contributes to dynamic disease evolution in glioblastoma. <i>Nature Genetics</i> , 2018, 50, 708-717.	9.4	212
11	TumorFusions: an integrative resource for cancer-associated transcript fusions. <i>Nucleic Acids Research</i> , 2018, 46, D1144-D1149.	6.5	179
12	PRADA: pipeline for RNA sequencing data analysis. <i>Bioinformatics</i> , 2014, 30, 2224-2226.	1.8	147
13	The Pan-Cancer analysis of pseudogene expression reveals biologically and clinically relevant tumour subtypes. <i>Nature Communications</i> , 2014, 5, 3963.	5.8	143
14	ZFH4 Interacts with the NuRD Core Member CHD4 and Regulates the Glioblastoma Tumor-Initiating Cell State. <i>Cell Reports</i> , 2014, 6, 313-324.	2.9	106
15	Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design. <i>Cell Reports</i> , 2019, 29, 1675-1689.e9.	2.9	103
16	Multigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma. <i>Neuro-Oncology</i> , 2017, 19, 786-795.	0.6	87
17	A modular master regulator landscape controls cancer transcriptional identity. <i>Cell</i> , 2021, 184, 334-351.e20.	13.5	78
18	A survey of intragenic breakpoints in glioblastoma identifies a distinct subset associated with poor survival. <i>Genes and Development</i> , 2013, 27, 1462-1472.	2.7	74

#	ARTICLE	IF	CITATIONS
19	Qki deficiency maintains stemness of glioma stem cells in suboptimal environment by downregulating endolysosomal degradation. <i>Nature Genetics</i> , 2017, 49, 75-86.	9.4	74
20	Integrated analysis of telomerase enzymatic activity unravels an association with cancer stemness and proliferation. <i>Nature Communications</i> , 2021, 12, 139.	5.8	39
21	Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma. <i>Cancer Research</i> , 2015, 75, 4131-4142.	0.4	38
22	Silent Mutations Make Some Noise. <i>Cell</i> , 2014, 156, 1129-1131.	13.5	33
23	Profiles of brain metastases: Prioritization of therapeutic targets. <i>International Journal of Cancer</i> , 2018, 143, 3019-3026.	2.3	31
24	M6A RNA Methylation Regulates Histone Ubiquitination to Support Cancer Growth and Progression. <i>Cancer Research</i> , 2022, 82, 1872-1889.	0.4	29
25	Studying a Complex Tumor. <i>Cancer Journal (Sudbury, Mass)</i> , 2012, 18, 107-114.	1.0	26
26	<i>EGFR</i> Amplification Induces Increased DNA Damage Response and Renders Selective Sensitivity to Talazoparib (PARP Inhibitor) in Glioblastoma. <i>Clinical Cancer Research</i> , 2020, 26, 1395-1407.	3.2	26
27	MSK1-Mediated β -Catenin Phosphorylation Confers Resistance to PI3K/mTOR Inhibitors in Glioblastoma. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1656-1668.	1.9	25
28	Signature-scoring methods developed for bulk samples are not adequate for cancer single-cell RNA sequencing data. <i>ELife</i> , 2022, 11, .	2.8	22
29	Opposing Tumor-Promoting and -Suppressive Functions of Rictor/mTORC2 Signaling in Adult Glioma and Pediatric SHH Medulloblastoma. <i>Cell Reports</i> , 2018, 24, 463-478.e5.	2.9	21
30	<i>ARID1B</i> alterations identify aggressive tumors in neuroblastoma. <i>Oncotarget</i> , 2017, 8, 45943-45950.	0.8	19
31	Tie2-FGFR1 Interaction Induces Adaptive PI3K Inhibitor Resistance by Upregulating Aurora A/PLK1/CDK1 Signaling in Glioblastoma. <i>Cancer Research</i> , 2019, 79, 5088-5101.	0.4	17
32	Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma. <i>Oncotarget</i> , 2017, 8, 21741-21753.	0.8	16
33	Prospective Clinical Sequencing of Adult Glioma. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 991-1000.	1.9	15
34	APOBEC3G acts as a therapeutic target in mesenchymal gliomas by sensitizing cells to radiation-induced cell death. <i>Oncotarget</i> , 2017, 8, 54285-54296.	0.8	15
35	Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution. <i>Nature Communications</i> , 2020, 11, 3669.	5.8	14
36	MYC Regulation of D2HGDH and L2HGDH Influences the Epigenome and Epitranscriptome. <i>Cell Chemical Biology</i> , 2020, 27, 538-550.e7.	2.5	14

#	ARTICLE	IF	CITATIONS
37	SNAI2-Mediated Repression of <i>BIM</i> Protects Rhabdomyosarcoma from Ionizing Radiation. <i>Cancer Research</i> , 2021, 81, 5451-5463.	0.4	13
38	TMIC-14. TUMOR EVOLUTION OF GLIOMA INTRINSIC GENE EXPRESSION SUBTYPE ASSOCIATES WITH IMMUNOLOGICAL CHANGES IN THE MICROENVIRONMENT. <i>Neuro-Oncology</i> , 2016, 18, vi202-vi202.	0.6	11
39	Benchmarking: contexts and details matter. <i>Genome Biology</i> , 2017, 18, 129.	3.8	9
40	PCAT: an integrated portal for genomic and preclinical testing data of pediatric cancer patient-derived xenograft models. <i>Nucleic Acids Research</i> , 2021, 49, D1321-D1327.	6.5	9
41	Approaches to identifying drug resistance mechanisms to clinically relevant treatments in childhood rhabdomyosarcoma. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2022, 5, 80-89.	0.9	2
42	Intragenic breakpoint. <i>Cell Cycle</i> , 2013, 12, 3705-3706.	1.3	1
43	Advances in Computational Genomics. <i>BioMed Research International</i> , 2015, 2015, 1-2.	0.9	0
44	GENO-36GLIOMA SPHERE-FORMING CELLS REVEAL INTRINSIC GLOBAL HYPERMETHYLATION ASSOCIATED WITH GBM RADIATION RESISTANCE. <i>Neuro-Oncology</i> , 2015, 17, v99.5-v100.	0.6	0
45	TMOD-31. AN INFLAMMATION RESPONSE GENE SIGNATURE IS ASSOCIATED WITH PROGNOSIS OF GLIOMA PATIENTS WITH 1p/19q CO-DELETION TUMORS. <i>Neuro-Oncology</i> , 2016, 18, vi213-vi213.	0.6	0